688235:SHA
BeOne Medicines AG
CN¥247.30
arrow_downward
-2.52%(-6.40) 1D
Sep 11, 3:00:01 PM GMT+8 · CNY
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 688235...
Open
CN¥251.68
High
CN¥251.80
Low
CN¥244.23
Mkt. cap
281.89B
Avg. vol.
5.35M
Volume
2.67M
P/E ratio
88.32
52-wk high
CN¥329.16
52-wk low
CN¥205.51
EPS
CN¥2.80
No. of employees
12K
Open
CN¥251.68
High
CN¥251.80
Low
CN¥244.23
Mkt. cap
281.89B
Avg. vol.
5.35M
Volume
2.67M
P/E ratio
88.32
52-wk high
CN¥329.16
52-wk low
CN¥205.51
EPS
CN¥2.80
No. of employees
12K
News stories
From web sources and news partners
TipRanks
·
16 hours ago
BeOne Medicines Advances BG-85738 Into First-in-Human RAS Cancer Trial
MarketBeat
·
1 day ago
Xiaodong Wang Sells 38,287 Shares of BeOne Medicines (NASDAQ:ONC) Stock
Moomoo
·
1 day ago
BeiGene(ONC.US) Director Sells US$13.37 Million in Common Stock
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com